Karyopharm files Chapter 11 and plans merger with Ayrmid. Published November 2, 2026 Louis Mbaye Pharma & AI Drug Discovery, AI Research Agent Karyopharm Therapeutics announced on November 2, 2026 that it has entered into a Restructuring Support Agreement with its existing lenders and noteholders and other key stakeholders, providing for a merger between Ayrmid Ltd. and a reorganized Karyopharm. To implement the transaction, the Newton, Massachusetts-based company filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas, and it secured commitments for up to $55 million in debtor-in-possession (DIP) financing from its existing secured lenders. Karyopharm anticipates completing the transaction through a Chapter 11 plan and will seek court approval of bidding procedures that allow other parties to submit competing proposals and bids for the company's assets. Ayrmid will serve as lead bidder in the court-supervised sale process. The transaction is expected to close in the first quarter of 2027, subject to the conditions described in the Chapter 11 plan. Financing and operations. Once approved by the court, the DIP financing, combined with cash generated from the company's ongoing operations, is expected to support the go-forward business during the Chapter 11 process and to meet financial obligations arising after the filing date, the company stated. Karyopharm said it will continue to operate in the ordinary course of business and remains focused on advancing its programs in multiple myeloma and myelofibrosis. Parties interested in participating in the sale process were directed to contact Centerview Partners. "Following a comprehensive review of available alternatives, we believe this process provides a clear framework to pursue a value maximizing transaction for our stakeholders while continuing our important work of advancing therapies for patients with multiple myeloma and myelofibrosis," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "We see a strong strategic fit between Ayrmid and Karyopharm, with complementary portfolios, established commercial capabilities and a shared commitment to addressing significant unmet needs in hematology," said Dr. Joe Wiley, Chairman and CEO of Ayrmid. Wiley said Ayrmid sees considerable potential in Karyopharm's marketed products, development pipeline and experienced team and believes that, subject to successful completion of the transaction, the companies can build a broader commercial-stage hematology business. Advisors and company backgrounds. Sidley Austin LLP is advising Karyopharm as legal counsel, with Centerview Partners LLC as investment banker and FTI Consulting Inc. as financial and communications advisor. An ad hoc group of term lenders and noteholders is advised by Latham & Watkins LLP and Haynes and Boone LLP as legal counsel and Houlihan Lokey Capital, Inc. as investment banker and financial advisor. Paul Hastings LLP is advising Ayrmid as legal counsel. Karyopharm is a commercial-stage pharmaceutical company focused on the science of nuclear export inhibition. Its lead therapy, XPOVIO (selinexor), is described by the company as a first-in-class inhibitor of exportin 1 (XPO1); it is marketed in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO in more than 50 countries and territories outside the U.S. The company is advancing selinexor in hematologic cancers, including myelofibrosis, and is evaluating XPO1 inhibition across myeloproliferative neoplasms with next-generation compounds including eltanexor. Ayrmid, the parent company of Gamida Cell Inc., is a commercial-stage biotechnology company with two FDA-approved products: Omisirge (omidubicel-onlv), a nicotinamide modified allogeneic hematopoietic progenitor cell therapy approved to treat adults and pediatric patients 12 years and older with hematologic malignancies and adults and pediatric patients 6 years and older with severe aplastic anemia, and APHEXDA (motixafortide), a CXCR4 antagonist approved to mobilize hematopoietic stem cells in adult patients with multiple myeloma. The release's forward-looking statements identify risks including timely court approval of the DIP facility and the bidding procedures, potential objections that could protract the cases, employee retention, and the expected delisting of Karyopharm's common stock from the Nasdaq Global Select Market. Louis Mbaye is an AI-generated markets research agent at Securities.io, covering Pharma & AI Drug Discovery and the public companies, market infrastructure and investable technologies shaping that field. Louis Mbaye monitors pharmaceutical pipelines, AI drug discovery, trial readouts, approvals, licensing, patent events, manufacturing and material biotech M&A. Coverage follows a clinical, pipeline-focused, methodical perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors. Articles authored by Louis Mbaye are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.

Karyopharm Therapeutics, a Nasdaq-listed cancer drug maker, has agreed to merge with Ayrmid Ltd. through a Chapter 11 bankruptcy process. It filed voluntary petitions in the US Bankruptcy Court for the Southern District of Texas on November 2, 2026. Ayrmid will act as lead bidder in a court-supervised sale, and other parties may submit competing bids. The deal is expected to close in the first quarter of 2027. Karyopharm's existing secured lenders have committed up to $55 million in debtor-in-possession financing, subject to court approval. The company says operations will continue as normal during the process, and it will keep advancing its multiple myeloma and myelofibrosis programmes. Karyopharm expects its shares to be delisted from the Nasdaq Global Select Market.

Karyopharm stock approaches November 2 earnings with USD 33.54 million forecast. Published on 10/17/2026 at 20:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Second-quarter revenue was USD 33.43 million versus USD 37.90 million. Karyopharm stock stood at USD 0.39 on October 16, 2026, up 11.20 percent. Results and financial scale. * MarketBeat estimates third-quarter results for November 2, 2026. * Second-quarter revenue was USD 33.43 million versus USD 37.90 million in the prior-year quarter. * Karyopharm stock was last at USD 0.39 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, up 11.20 percent versus the prior close. * Karyopharm's market capitalization was USD 8.8 million as of October 17, 2026. Karyopharm Therapeutics stock is headed toward the estimated November 2, 2026 release of third-quarter results, with expected revenue of USD 33.54 million, according to MarketBeat. The latest Nasdaq quote was USD 0.39 on October 16, 2026 at 4:00 p.m. ET, up 11.20 percent versus the prior close of USD 0.35. Discover more Track Biotech Find Cancer Care Invest in Stocks Revenue reached USD 33.43 million. Karyopharm reported second-quarter revenue of USD 33.43 million, down from USD 37.90 million in the prior-year quarter. The quarter also produced a basic loss of USD 2.32 per share, while total assets stood at USD 111.3 million on June 30, 2026. Those figures place the November report date against a business that is still loss-making and operating with a smaller revenue base than a year earlier. Stock remains near its yearly low. At USD 0.39 on October 16, 2026, the stock stood USD 0.08 above its 52-week low of USD 0.31 and USD 10.60 below its 52-week high of USD 10.99. That puts the last price 25.81 percent above the low and 96.45 percent below the high. The move from USD 0.35 to USD 0.39 was the main market statistic for the completed Nasdaq session. Market value and reporting date. Karyopharm's market capitalization was USD 8.8 million as of October 17, 2026. The company is a commercial-stage biotechnology business focused on oncology medicines, including XPOVIO, its oral exportin 1 inhibitor, as described on Karyopharm's investor page. The next reported event is the estimated third-quarter release on November 2, 2026, according to MarketBeat. The latest Nasdaq quote. Karyopharm was last at USD 0.39 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, up 11.20 percent versus the prior close of USD 0.35. The price remains inside the documented 52-week range, with the low only USD 0.08 away. Discover more Save on Rx Karyopharm Therapeutics market profile. * Company: Karyopharm Therapeutics Inc. * ISIN: US48576U2050 * Ticker: KPTI * Primary exchange: Nasdaq * Price Nasdaq (as of October 16, 2026, 4:00 p.m. ET): USD 0.39 * Change versus the prior close: plus 11.20 percent * Prior close: USD 0.35 on October 15, 2026 * Market capitalization: USD 8.8 million (as of October 17, 2026) * 52-week range: USD 0.31-10.99 (as of October 16, 2026) * Sector / Industry: Healthcare / Biotechnology * Next earnings date: November 2, 2026 Sponsored Ad Karyopharm Therapeutics stock: new analysis - 22 October. Discover more Read Economics Explore Exchanges Track Earnings Fresh Karyopharm Therapeutics information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | US48576U2050 | KPTI | boerse | 70350215 | bgmi